Oruka Therapeutics, Inc. short interest in 2019
In 2019, Oruka Therapeutics, Inc.'s disclosed short interest ran from 2.64% of shares outstanding on 15 Jan 2019 to 0.35% on 31 Dec 2019, a change of -2.29 percentage points. The year's high was 14.46% on 15 May 2019 and its low 0.25% on 31 Oct 2019, averaging 2.46% across 15 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 5.52 days on 31 Jan 2019. Full history: Oruka Therapeutics, Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2019 in figures
- Start of year
- 2.64% (15 Jan 2019)
- End of year
- 0.35% (31 Dec 2019)
- Change
- -2.29 pp
- High
- 14.46% (15 May 2019)
- Low
- 0.25% (31 Oct 2019)
- Average
- 2.46%
- Highest days to cover
- 5.52 (31 Jan 2019)
- SEC filings marked
- 11
Every report in 2019
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2019 | 2.64% | 2.52 | |
| 31 Jan 2019 | 2.61% | 5.52 | |
| 15 Feb 2019 | 2.99% | 2.39 | |
| 28 Feb 2019 | 3.44% | 1.00 | results (8-K), 10-K filed, results (8-K) |
| 15 Mar 2019 | 3.00% | 1.00 | |
| 29 Mar 2019 | 3.21% | 1.00 | |
| 15 May 2019 | 14.46% | 1.00 | 10-Q filed, results (8-K) |
| 31 Jul 2019 | 0.88% | 1.00 | results (8-K), results (8-K) |
| 15 Aug 2019 | 0.98% | 1.00 | 10-Q filed, results (8-K) |
| 30 Aug 2019 | 0.58% | 1.00 | |
| 30 Sep 2019 | 0.58% | 1.00 | |
| 31 Oct 2019 | 0.25% | 1.00 | |
| 15 Nov 2019 | 0.36% | 1.00 | 10-Q filed, results (8-K) |
| 13 Dec 2019 | 0.55% | 1.00 | |
| 31 Dec 2019 | 0.35% | 1.00 |
See also: Oruka Therapeutics, Inc.'s full history · most shorted US stocks of 2019 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.